Unknown

Dataset Information

0

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma.


ABSTRACT: Ovarian cancer is one of the leading causes of deaths among patients with gynecological malignancies worldwide. In order to identify prognostic markers for ovarian cancer, we performed RNA-sequencing and analyzed the transcriptome data from 51 patients who received conventional therapies for high-grade serous ovarian carcinoma (HGSC). Patients with early-stage (I or II) HGSC exhibited higher immune gene expression than patients with advanced stage (III or IV) HGSC. In order to predict the prognosis of patients with HGSC, we created machine learning-based models and identified USP19 and RPL23 as candidate prognostic markers. Specifically, patients with lower USP19 mRNA levels and those with higher RPL23 mRNA levels had worse prognoses. This model was then used to analyze the data of patients with HGSC hosted on The Cancer Genome Atlas; this analysis validated the prognostic abilities of these two genes with respect to patient survival. Taken together, the transcriptome profiles of USP19 and RPL23 determined using a machine-learning model could serve as prognostic markers for patients with HGSC receiving conventional therapy.

SUBMITTER: Kang H 

PROVIDER: S-EPMC8391231 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>USP19</i> and <i>RPL23</i> as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma.

Kang Haeyoun H   Choi Min Chul MC   Kim Sewha S   Jeong Ju-Yeon JY   Kwon Ah-Young AY   Kim Tae-Hoen TH   Kim Gwangil G   Joo Won Duk WD   Park Hyun H   Lee Chan C   Song Seung Hun SH   Jung Sang Geun SG   Hwang Sohyun S   An Hee Jung HJ  

Cancers 20210806 16


Ovarian cancer is one of the leading causes of deaths among patients with gynecological malignancies worldwide. In order to identify prognostic markers for ovarian cancer, we performed RNA-sequencing and analyzed the transcriptome data from 51 patients who received conventional therapies for high-grade serous ovarian carcinoma (HGSC). Patients with early-stage (I or II) HGSC exhibited higher immune gene expression than patients with advanced stage (III or IV) HGSC. In order to predict the progno  ...[more]